 Home > Active Ingredient News > Blood System > J Clin Oncol: Brentuximab combined with AVD regimen in the treatment of newly diagnosed early-stage Hodgkin's lymphoma with a risk of poor prognosis

J Clin Oncol: Brentuximab combined with AVD regimen in the treatment of newly diagnosed early-stage Hodgkin's lymphoma with a risk of poor prognosis

 Last Update: 2021-05-08
 Source: Internet
 Author: User

Tags

red blood cell model

risk management services

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

For a long time, the combined treatment plan has been used as the standard treatment plan for early stage (ES), mass Hodgkin's lymphoma (HL) with a risk of poor prognosis , that is, chemotherapy + radiotherapy.

Lymphoma

In order to improve the curability of newly diagnosed Hodgkin's lymphoma with adverse prognostic factors and limit its long-term adverse effects, Kumar et al.

In this study, patients with Hodgkin’s lymphoma at an early stage and at risk of poor prognosis received 4 courses of Brentuximab (BV) and doxorubicin, vinblastine, and dacarbazine (AVD).

Research Process

A total of 117 patients were recruited, 116 of whom completed chemotherapy.

PFS and OS

The complete remission rates of cohorts 1-4 were 93%, 100%, 93%, and 97%, respectively.

In short, the 4-course combination of BV and AVD is well tolerated in ES and Hodgkin’s lymphoma patients with a risk of poor prognosis, and has high therapeutic activity .

The 4-course combination of BV and AVD is well tolerated in ES and Hodgkin’s lymphoma patients at risk of poor prognosis, and it has high therapeutic activity.

Original source:

Anita Kumar, et al.

org/doi/full/10.
1200/JCO.
21.
00108" target="_blank" rel="noopener">Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Atipamezole hydrochloride 104075-48-1 reduce sedation lower blood pressure

CAS No.: 104075-48-1

Pharm grade

$1/G EXW

Pharma Grade Fasudil hydrochloride CAS:105628-07-7 for High Purity

CAS No.: 105628-07-7

Pharmacy Grade;

$4.8-5.5/G FOB

Nutritional Supplement Chemicals Whey Protein CAS:91082-88-1/84082-51-9 for Food Grdade

CAS No.: 84082-51-9

Pharmacy Grade;

$40-50/KG FOB

Hot Tags

jobs united states(236)

united states jobs(223)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

ups united states(221)

announcements today(81)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.